



Gene Therapy Coming of Age

Guest Editor:

Dr. Kenneth Lundstrom

PanTherapeutics, Rue des
Remparts 4, CH1095 Lutry,
Switzerland

Deadline for manuscript
submissions:

closed (31 March 2021)

Message from the Guest Editor

Dear Colleagues,

Gene therapy was once considered as the medicine of the future, back in the late 1990s, but it then suffered some unexpected setbacks in terms of virus-based delivery approaches. Nevertheless, gene therapy is now experiencing a second coming due to its improved efficacy and safety of vector delivery. This has led to the initiation of a large number of clinical trials and even approval of the first gene therapy drugs. Furthermore, recent progress in RNA interference, RNA delivery, and gene-editing technologies has broadened the application range of gene therapy. Today, both viral and nonviral vectors have found various applications for treatment of several diseases, such as cancer, metabolic, neurodegenerative, cardiovascular, and muscular diseases. The Special Issue on Gene Therapy in *Biomedicines* is therefore a particularly topical addition to the field, providing up-to-date insight into delivery vector types, safety-related issues, proof-of-principle in preclinical disease models, clinical trials in healthy volunteers and patients, and approval of gene therapy-based drugs.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)